Quest Diagnostics Is Down 10%. What History Says Now.

Quest Diagnostics Just Recovered From Its Worst Pullback of 2026. What History Says.

Quest Diagnostics Incorporated (DGX) has officially exited the yellow zone and returned to the green zone as of May 19, 2026. This recovery marks a significant shift in the stock's risk profile after a period of heightened volatility that saw the share price struggle to maintain momentum. The stock currently sits at $190.39, representing a recovery process that has been unfolding over the last 56 days.

The Anatomy of the DGX Pullback

The recent decline took Quest Diagnostics Incorporated (DGX) from its all-time high of $211.91 down to its current level, resulting in a current drawdown of -10.2%. During this 56-day stretch, our data tracked the stock as it moved into the yellow zone, indicating a period where the risk of further decline was statistically elevated compared to its historical norms.

The Drawdown Severity Score™ has now improved to 2.0, which we categorize as Slightly Elevated. While a score of 2.0 remains within the green zone, it suggests that while the immediate "yellow zone" threat has subsided, the stock is still working through the tail end of this specific drawdown cycle. This 56-day duration is slightly longer than the company's historical average drawdown duration of 53 days, suggesting this particular move was stickier than a standard minor fluctuation.

Shifting Fundamentals and Market Sentiment

The transition back to the green zone coincides with a shift in the fundamental narrative surrounding the company. According to PR Newswire, Quest Diagnostics recently reported first quarter 2026 financial results where they raised both revenue and EPS guidance for the full year. This guidance hike appears to have provided the necessary floor for the stock price to stabilize.

Market analysts have also noted a change in how the company is being valued following the recent price action. Yahoo Finance reports that the investment narrative for Quest Diagnostics (DGX) is shifting as new valuation work suggests the pullback may have realigned the stock with its long-term growth prospects. Additionally, Investor’s Business Daily highlighted the "stock-spiking" nature of the first-quarter report as the most impressive aspect of the company’s recent performance, providing the catalyst needed to push the Drawdown Severity Score™ back into safer territory.

Putting a 10% Drawdown in Historical Context

To understand the significance of a -10.2% drawdown for this specific asset, we must look at the 192 historical drawdown events we have recorded for Quest Diagnostics (DGX). On average, a typical drawdown for this stock results in a maximum decline of -5.5%. The current -10.2% drop is nearly double the historical average, explaining why the severity score previously escalated into the yellow zone.

While the current decline is deeper than average, it remains far from the "worst-case" scenarios seen in the company's history. Our data shows that Quest Diagnostics (DGX) has dropped 30% or more exactly 8 times in its trading history. When the stock enters those deep-drawdown regimes, the recovery process is significantly more grueling, with an average duration of 549 days to return to previous highs.

The fact that the current drawdown has lasted only 56 days and is already showing signs of severity improvement suggests this move is a standard correction rather than a fundamental breakdown. Historically, when DGX manages to stabilize within the 50 to 60-day window, it avoids the prolonged multi-hundred-day recovery cycles associated with its more severe historical crashes.

Monitoring the Path to a Full Recovery

Although the move from the yellow zone to the green zone is a positive signal for risk management, Quest Diagnostics (DGX) is not yet "out of the woods" in terms of reaching a new high. The stock remains -10.2% below its peak of $211.91. For the Drawdown Severity Score™ to return to a 0.0, the stock must fully erase this deficit.

We continue to monitor the activity of institutional holders, as these moves often precede shifts in drawdown zones. For instance, MarketBeat recently reported that the Canada Post Corp Registered Pension Plan sold 5,785 shares of Quest Diagnostics (DGX). While this specific sale is relatively small, consistent institutional selling can often stall a recovery and push a stock back into the yellow or red zones.

Conversely, the stock's reputation as a reliable income generator remains a primary support pillar. ChartMill recently described Quest Diagnostics (DGX) as a solid dividend play backed by strong profitability and financial health. This "flight to safety" characteristic often helps DGX find buyers during market-wide pullbacks, preventing the Drawdown Severity Score™ from reaching the extreme levels seen in higher-beta healthcare stocks.

What to Watch Next

Investors should keep a close eye on the $211.91 level. A move toward this price would continue to lower the Drawdown Severity Score™ and reinforce the green zone status. However, if the stock fails to maintain its current momentum and the drawdown deepens beyond the current -10.2%, we would expect the severity score to climb back toward the yellow zone threshold.

Our data indicates that the current recovery is tracking closely with the average historical recovery time for pullbacks of this magnitude, provided the broader market remains stable. Because the stock has already surpassed its average drawdown duration of 53 days, the next few weeks are critical for determining if this recovery will be swift or if Quest Diagnostics (DGX) will enter a period of prolonged consolidation.